Get the Stockscreener App
1.25
3.85%
-0.05
NanoViricides Inc stock is traded at $1.25, with a volume of 315.89K.
It is down -3.85% in the last 24 hours and down -16.67% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.30
Open:
$1.3
24h Volume:
315.89K
Relative Volume:
1.04
Market Cap:
$22.50M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.7857
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+1.63%
1M Performance:
-16.67%
6M Performance:
-17.22%
1Y Performance:
-14.97%
1-Day Range:
$1.25
$1.30
1-Week Range:
$1.23
$1.49
52-Week Range:
$0.94
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.25 | 23.40M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - Daytona Beach News-Journal
Belarus frees Nobel laureate Ales Bialiatksi and opposition figure Maria Kolesnikova from prison, rights group confirms - Barchart.com
Applied Digital, Benchmark, Knowles, Cognex, and Flex Stocks Trade Down, What You Need To Know - Barchart.com
Shootin' the Bull about wait and see - Barchart.com
2 Small-Cap Biotechs That Could Reward Patient Investors - Investing.com
EU indefinitely freezes Russian assets to stop Moscow-friendly Hungary and Slovakia from vetoing their use for Ukraine - Barchart.com
2 Small-Cap Biotechs That Could Reward Patient Investors - MarketBeat
Is Clorox Stock Underperforming the S&P 500? - Barchart.com
Is J.B. Hunt Transport Services Stock Outperforming the Dow? - Barchart.com
Americans, including many in Trump’s base, overwhelmingly see higher holiday prices than normal, an AP-NORC poll finds - Barchart.com
Is Hologic Stock Outperforming the Nasdaq? - Barchart.com
How Is VeriSign’s Stock Performance Compared to Other Software Stocks? - Barchart.com
NanoViricides Holds 2025 Annual Stockholders Meeting - MSN
US sanctions 3 nephews of Venezuelan President Maduro as Trump further ramps up pressure on South American nation - Barchart.com
This AI Stock Has 45% Upside Potential and No One Is Talking About It Yet - Barchart.com
How Is Best Buy's Stock Performance Compared to Other Specialty Retail Stocks? - Barchart.com
Corpay Stock: Is CPAY Underperforming the Technology Sector? - Barchart.com
3 Reasons EYE is Risky and 1 Stock to Buy Instead - Barchart.com
Omnicom Group (OMC) Stock Is Up, What You Need To Know - Barchart.com
Is Veralto Corporation Stock Underperforming the S&P 500? - Barchart.com
Is Steel Dynamics Stock Outperforming the Dow? - Barchart.com
Is PTC Stock Underperforming the Nasdaq? - Barchart.com
Is Invitation Homes Stock Underperforming the Dow? - Barchart.com
Is Teradyne Stock Outperforming the Nasdaq? - Barchart.com
Is Cardinal Health Stock Outperforming the Nasdaq? - Barchart.com
Chewy (NYSE:CHWY) Surprises With Q3 CY2025 Sales - Barchart.com
Is FirstEnergy Stock Underperforming the S&P 500? - Barchart.com
How Is Rollins’ Stock Performance Compared to Other Cyclical Stocks? - Barchart.com
GBPUSD Extends Rally As Bullish Impulse Builds - Barchart.com
3 Inflated Consumer Stocks That Concern Us - Barchart.com
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Savannah Morning News
Apple Stock Marks a Solid Comeback. Is AAPL a Buy, Sell, or Hold for 2026? - Barchart.com
Marvell Soars 32% in 3 Months — Is MRVL Stock a Buy, Sell, or Hold? - Barchart.com
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Enterprise News
Why Are Revolve (RVLV) Shares Soaring Today - Barchart.com
Upwork (UPWK) Stock Is Up, What You Need To Know - Barchart.com
Why Flex (FLEX) Stock Is Up Today - Barchart.com
This Clinical-Stage Biotech Just Raised $6M to Advance a Drug That Could Address Pandemic Preparedness Gaps - Barchart.com
DiagnosTear Technologies Inc.Confirmation of No Material Change - Barchart.com
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricidesNV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus - York Dispatch
Stocks in play: Parex Resources Inc. - Barchart.com
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Reuters
NanoViricides Inc Stock Analysis and ForecastGlobal Trade Effects & Free Get Breakthrough Ideas - earlytimes.in
Upstart (UPST): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Oracle Earnings: What To Look For From ORCL - Barchart.com
Strategy Inc. Buys 10,624 More Bitcoin, Lifts Holdings to 660,624 BTC - Barchart.com
Stocks in play: Aurora Cannabis Inc. - Barchart.com
Is L3Harris Technologies Stock Underperforming the Nasdaq? - Barchart.com
EURNZD May Have Topped - Barchart.com
Is Rockwell Automation Stock Outperforming the Dow? - Barchart.com
3 Volatile Stocks Walking a Fine Line - Barchart.com
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):